TOKYO (Reuters) - Mitsubishi Chemical Holdings Corp (4188.T), Japan’s largest chemical maker, said on Monday it will pay 491.8 billion yen ($4.51 billion) to make Mitsubishi Tanabe Pharma Corp (4508.T) a fully owned subsidiary.
Mitsubishi Chemical will offer 2,010 yen for each share it doesn’t already own in Mitsubishi Tanabe, it said in a statement to the Tokyo Stock Exchange. That is a 50% premium to the drugmaker’s closing price of 1,338 yen per share in Tokyo trading.
The chemical maker already held more than 56% of shares in Mitsubishi Tanabe, Japan’s eighth largest drugmaker by revenue, according to Refinitiv data.
The Osaka-based pharma company was the product of a 2007 merger between Mitsubishi Pharma Corp and Tanabe Seiyaku. It focuses on autoimmune, diabetes, renal and central nervous system treatments.
Reporting by Rocky Swift; Editing by Muralikumar Anantharaman